A Phase I Study of QL1604 for Advanced Solid Tumors

Summary

In this study, patients with advance solid tumors will be treated with QL1604 monotherapy.

Timeline

Start

2020-07-20

Primary completion

2023-04-15

Completion

2023-12-15

Publications

• Xiong J, Ouyang W, Yang M, Gao Z, Zhou H, Lou H, Guo Y, Xu Z, Zheng L, Liu Y, Wang Z, Sun P, Niyazi H, Wang J, Chen Y, Zhang B, Li L, Kang X, Guo W. Efficacy and Safety of Iparomlimab, an Anti-PD-1 Antibody, in Patients with Advanced Solid Tumors: A Phase 1c Study. Adv Ther. 2024 Nov;41(11):4153-4171. doi: 10.1007/s12325-024-02981-z. Epub 2024 Sep 14.

Drugs

Indications